"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How do these bad drugs get to our patients?" Congressional Briefing, March 7-8, 2016
A presentation by Tom T. Kubic, President and CEO, Pharmaceutical Security Institute and Treasurer, Partnership for Safe Medicines about the threat of imported counterfeit prescription drugs.
This document discusses the threats posed by counterfeit medicines. It provides several examples of counterfeit medicines breaching the US supply chain and being distributed through "Canadian" websites and social media sites. The counterfeits have been found to contain no active ingredients, toxic ingredients, or incorrect doses of active ingredients. They are manufactured under unsafe conditions but can appear virtually indistinguishable from real medicines. The document emphasizes that counterfeit medicines pose a real threat to patient health and safety.
A presentation by J. Aaron Graham, Executive Director of Brand Safety & Security at Boehringer Ingelheim Pharmaceuticals, Inc., about the threat of imported counterfeit prescription drugs.
This document discusses Maine's experience with LD 171, a law passed in 2013 to legalize the importation of prescription drugs from licensed pharmacies in Canada, UK, Australia and New Zealand. It describes how the Maine Pharmacy Association President ordered drugs from an online Canadian pharmacy called Canada Drug Center and found the drugs to be substandard and contaminated. The law was struck down in 2015 because it compromised federal drug regulation. Attempts by other states to import drugs from foreign pharmacies similarly found poor oversight, unsafe drugs, and an inability to regulate foreign entities.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, U.S. Department of Justice speaks around criminal prosecutions of drug counterfeiters and diverters in the US.
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs -Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
In this presentation, Director of National Outreach Shabbir Imber Safdar reviews the current state of counterfeit drugs in America today, discusses some of the myths surrounding importation, and provides tips for saving money safely on the cost of prescription drugs.
This document discusses the threats posed by counterfeit medicines. It provides several examples of counterfeit medicines breaching the US supply chain and being distributed through "Canadian" websites and social media sites. The counterfeits have been found to contain no active ingredients, toxic ingredients, or incorrect doses of active ingredients. They are manufactured under unsafe conditions but can appear virtually indistinguishable from real medicines. The document emphasizes that counterfeit medicines pose a real threat to patient health and safety.
A presentation by J. Aaron Graham, Executive Director of Brand Safety & Security at Boehringer Ingelheim Pharmaceuticals, Inc., about the threat of imported counterfeit prescription drugs.
This document discusses Maine's experience with LD 171, a law passed in 2013 to legalize the importation of prescription drugs from licensed pharmacies in Canada, UK, Australia and New Zealand. It describes how the Maine Pharmacy Association President ordered drugs from an online Canadian pharmacy called Canada Drug Center and found the drugs to be substandard and contaminated. The law was struck down in 2015 because it compromised federal drug regulation. Attempts by other states to import drugs from foreign pharmacies similarly found poor oversight, unsafe drugs, and an inability to regulate foreign entities.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Linda I. Marks, Senior Litigation Counsel, Consumer Protection Branch, U.S. Department of Justice speaks around criminal prosecutions of drug counterfeiters and diverters in the US.
Scott A. LaGanga, Executive Director Partnership for Safe Medicines (PSM) and Senior Vice President, Public Affairs -Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), opens PSM's Interchange 2014.
In this presentation, Director of National Outreach Shabbir Imber Safdar reviews the current state of counterfeit drugs in America today, discusses some of the myths surrounding importation, and provides tips for saving money safely on the cost of prescription drugs.
In this webinar I provide an overview of counterfeits in America, I talk about some myths of importation, and I teach patients and patient advocates some great tips for saving money safely.
The document discusses the dangers American patients face from counterfeit medications obtained outside of the regulated US drug supply chain, such as through fake online Canadian pharmacies. It details how breaks in the secure supply chain, such as patients buying drugs online or some doctors and pharmacists obtaining drugs from unlicensed distributors, can endanger patients by exposing them to counterfeit and unsafe medications. The document aims to dispel myths about obtaining cheaper drugs from outside the US and provides tips for patients to stay safe.
Online Access to Safe and Affordable Medication: Applying human rights law to...PharmacyChecker
Online Access to Safe and Affordable Medication: Applying human rights law to cyber rule-making and Internet governance
https://www.pharmacychecker.com/
Internet users are benefiting from online access to safe and affordable medications. The pharmaceutical industry views Internet access as a threat and disruptive to its profit model because consumers are paying less than the drug companies intended for them to pay. According to the UN Human Rights Council, access to affordable medication is a human right. As the Internet community seeks to infuse the principles of international human rights law into the discourse and practice of Internet governance it should help maintain the widest possible online access to safe and affordable medication.
https://www.pharmacychecker.com/
Counterfeit drugs pose a major global problem and public health risk. According to the World Health Organization, over half of counterfeit drug cases found no active ingredients, while others contained incorrect or dangerous ingredients. Developing countries are especially impacted, with up to 60% of reported counterfeit drugs. Counterfeiting undermines healthcare systems and can have deadly consequences. The document warns that weak drug regulation and an unsecured supply chain allow for counterfeits to proliferate. It advocates purchasing from authorized drug distributors only to help strengthen oversight of the pharmaceutical supply system.
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
Daniel Burke, FDA's Senior Special Agent in the Cybercrime Investigations Unit, introduces our 3rd panel at the 2014 Interchange by speaking about how fake online pharmacies can affect American citizens.
This presentation is designed to train patient advocates in the safety issues around counterfeit drugs: how counterfeits enter our supply chain and how patients can protect themselves.
This document discusses ethical issues with the pricing of drugs by US pharmaceutical companies. It provides examples of Valeant Pharmaceuticals and Turing Pharmaceuticals dramatically increasing prices of older drugs. While legal, these actions seem unethical given lack of investment in research. Congress is investigating if drugmakers are price gouging. There is debate around government regulation of drug prices to balance innovation and accessibility.
June 19, 2013: This presentation to highlight the dangers of counterfeit drugs to Maine patients was given to the Bangor Dept. of Health Public Advisory committee
This document discusses the Partnership for Safe Medicines, an organization advocating for safe medication access. It lists over 100 member organizations and provides information on counterfeit drugs including examples during the COVID-19 pandemic of fake vaccines, testing kits, and medicines being sold. Data is presented on rising drug overdose deaths in the US driven largely by fentanyl, and examples are given of recent seizures of counterfeit pills containing fentanyl in various states and countries that are fueling the opioid crisis.
Ethical dilemmas concerning drug pricing-Shrinath GhadgeShrinath Ghadge
There is no straightforward solution to the proper pricing of a pharmaceutical. Numerous factors influence pricing from the company perspective such as return on investment, costs of future R&D efforts, access to federal funding, and size of the patient population, to name a few. In addition the healthcare system in the US is generally much more expensive than other countries, driving up overall costs. A public distrust of pharmaceutical companies' greed has been fueled by recent cases of exorbitant increases in drug prices without clear cause. These instances do raise questions of the ethics employed by some companies
The document describes a study using the Agilent 6230 TOF mass spectrometer to screen for 15 drugs listed in the UK Drug Driving Law in blood samples. An all-ions MS/MS method was developed that utilized in-source fragmentation and an accurate mass MS/MS library to identify compounds through fragment matching down to a limit of detection of 2ng/mL, meeting or exceeding the threshold limits in the law.
Best Practices for Traditional Chinese Medicine Companies to Improve Traceabi...Alfons Futterer
Get insights into the latest traceability and brand protection technologies on traditional Chinese medicine.
Through this webinar presentation you’ll learn about:
- Counterfeit drugs and fake Chinese traditional medicine statistics
- Technologies
An in-depth study on the patent litigation in Pharma & Biotech industry in 2014.
See who were the top defendants and the top plaintiffs. Patent litigation suits filed by year, by court, by law-firms, by region, etc.
This document summarizes a presentation on using prescription drug data to limit misuse and abuse by third-party payers. The presentation features speakers from myMatrixx and Express Scripts discussing how data from sources like prescription drug monitoring programs, the DEA, NPPES, proprietary databases, and pharmaceutical manufacturers can be mined and analyzed to identify problematic prescribing patterns, problem geographic areas, and individual doctors who may be recklessly prescribing controlled substances. The goal is to organize collaboration between private and public agencies to help address the epidemic of prescription drug abuse.
I have been working on the topic of anti-counterfeiting for a number of years and find myself increasingly engrossed and thoroughly surprised as our understanding of this topic grows. The imagination and the brutality with which the criminal industry produces, distributes and sells imitation goods is unmatched. The consequences of such dire acts are not only killing children but also affecting the lives of many and fighting such forgery has become a personal battle for me.
The document discusses Maine laws regarding importing prescription drugs from licensed pharmacies in other countries. It states that licensed pharmacies in Canada, UK, Australia, and New Zealand can export prescription drugs by mail to Maine residents for personal use without a Maine license. It also states that entities that facilitate drug exports from these licensed foreign pharmacies to Maine residents are also exempt from needing a Maine license. The document then lists information about specific drugs' manufacturers, fill centers, and mailing addresses.
This presentation was the main portion of a March 15th, 2012 Congressional briefing in Washington DC on the state of counterfeits in America and the details, as currently known, of the fake Avastin incident.
In this webinar I provide an overview of counterfeits in America, I talk about some myths of importation, and I teach patients and patient advocates some great tips for saving money safely.
The document discusses the dangers American patients face from counterfeit medications obtained outside of the regulated US drug supply chain, such as through fake online Canadian pharmacies. It details how breaks in the secure supply chain, such as patients buying drugs online or some doctors and pharmacists obtaining drugs from unlicensed distributors, can endanger patients by exposing them to counterfeit and unsafe medications. The document aims to dispel myths about obtaining cheaper drugs from outside the US and provides tips for patients to stay safe.
Online Access to Safe and Affordable Medication: Applying human rights law to...PharmacyChecker
Online Access to Safe and Affordable Medication: Applying human rights law to cyber rule-making and Internet governance
https://www.pharmacychecker.com/
Internet users are benefiting from online access to safe and affordable medications. The pharmaceutical industry views Internet access as a threat and disruptive to its profit model because consumers are paying less than the drug companies intended for them to pay. According to the UN Human Rights Council, access to affordable medication is a human right. As the Internet community seeks to infuse the principles of international human rights law into the discourse and practice of Internet governance it should help maintain the widest possible online access to safe and affordable medication.
https://www.pharmacychecker.com/
Counterfeit drugs pose a major global problem and public health risk. According to the World Health Organization, over half of counterfeit drug cases found no active ingredients, while others contained incorrect or dangerous ingredients. Developing countries are especially impacted, with up to 60% of reported counterfeit drugs. Counterfeiting undermines healthcare systems and can have deadly consequences. The document warns that weak drug regulation and an unsecured supply chain allow for counterfeits to proliferate. It advocates purchasing from authorized drug distributors only to help strengthen oversight of the pharmaceutical supply system.
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
Daniel Burke, FDA's Senior Special Agent in the Cybercrime Investigations Unit, introduces our 3rd panel at the 2014 Interchange by speaking about how fake online pharmacies can affect American citizens.
This presentation is designed to train patient advocates in the safety issues around counterfeit drugs: how counterfeits enter our supply chain and how patients can protect themselves.
This document discusses ethical issues with the pricing of drugs by US pharmaceutical companies. It provides examples of Valeant Pharmaceuticals and Turing Pharmaceuticals dramatically increasing prices of older drugs. While legal, these actions seem unethical given lack of investment in research. Congress is investigating if drugmakers are price gouging. There is debate around government regulation of drug prices to balance innovation and accessibility.
June 19, 2013: This presentation to highlight the dangers of counterfeit drugs to Maine patients was given to the Bangor Dept. of Health Public Advisory committee
This document discusses the Partnership for Safe Medicines, an organization advocating for safe medication access. It lists over 100 member organizations and provides information on counterfeit drugs including examples during the COVID-19 pandemic of fake vaccines, testing kits, and medicines being sold. Data is presented on rising drug overdose deaths in the US driven largely by fentanyl, and examples are given of recent seizures of counterfeit pills containing fentanyl in various states and countries that are fueling the opioid crisis.
Ethical dilemmas concerning drug pricing-Shrinath GhadgeShrinath Ghadge
There is no straightforward solution to the proper pricing of a pharmaceutical. Numerous factors influence pricing from the company perspective such as return on investment, costs of future R&D efforts, access to federal funding, and size of the patient population, to name a few. In addition the healthcare system in the US is generally much more expensive than other countries, driving up overall costs. A public distrust of pharmaceutical companies' greed has been fueled by recent cases of exorbitant increases in drug prices without clear cause. These instances do raise questions of the ethics employed by some companies
The document describes a study using the Agilent 6230 TOF mass spectrometer to screen for 15 drugs listed in the UK Drug Driving Law in blood samples. An all-ions MS/MS method was developed that utilized in-source fragmentation and an accurate mass MS/MS library to identify compounds through fragment matching down to a limit of detection of 2ng/mL, meeting or exceeding the threshold limits in the law.
Best Practices for Traditional Chinese Medicine Companies to Improve Traceabi...Alfons Futterer
Get insights into the latest traceability and brand protection technologies on traditional Chinese medicine.
Through this webinar presentation you’ll learn about:
- Counterfeit drugs and fake Chinese traditional medicine statistics
- Technologies
An in-depth study on the patent litigation in Pharma & Biotech industry in 2014.
See who were the top defendants and the top plaintiffs. Patent litigation suits filed by year, by court, by law-firms, by region, etc.
This document summarizes a presentation on using prescription drug data to limit misuse and abuse by third-party payers. The presentation features speakers from myMatrixx and Express Scripts discussing how data from sources like prescription drug monitoring programs, the DEA, NPPES, proprietary databases, and pharmaceutical manufacturers can be mined and analyzed to identify problematic prescribing patterns, problem geographic areas, and individual doctors who may be recklessly prescribing controlled substances. The goal is to organize collaboration between private and public agencies to help address the epidemic of prescription drug abuse.
I have been working on the topic of anti-counterfeiting for a number of years and find myself increasingly engrossed and thoroughly surprised as our understanding of this topic grows. The imagination and the brutality with which the criminal industry produces, distributes and sells imitation goods is unmatched. The consequences of such dire acts are not only killing children but also affecting the lives of many and fighting such forgery has become a personal battle for me.
The document discusses Maine laws regarding importing prescription drugs from licensed pharmacies in other countries. It states that licensed pharmacies in Canada, UK, Australia, and New Zealand can export prescription drugs by mail to Maine residents for personal use without a Maine license. It also states that entities that facilitate drug exports from these licensed foreign pharmacies to Maine residents are also exempt from needing a Maine license. The document then lists information about specific drugs' manufacturers, fill centers, and mailing addresses.
This presentation was the main portion of a March 15th, 2012 Congressional briefing in Washington DC on the state of counterfeits in America and the details, as currently known, of the fake Avastin incident.
Tim Mackey presented on the availability of dangerous, unapproved, and recalled drugs online. Some key points:
- Research has found narrow therapeutic index drugs, drugs not approved for sale, and drugs under global recall are actively being marketed for sale without a prescription online.
- The online drug ecosystem is complex, involving affiliate networks, business-to-business sellers, and emerging technologies like the dark web.
- Moving forward, efforts should identify high-risk dangerous drugs, develop global lists of such drugs, map the entire illicit online pharmacy ecosystem, and prioritize enforcement against the worst offenders. The goal is to improve identification, surveillance and enforcement of clearly dangerous medicines available online without oversight.
The document summarizes the 2013 Interchange conference hosted by the Partnership for Safe Medicines (PSM). It lists the executive director of PSM and its many member organizations. It then describes PSM's efforts over the past year to educate over 300,000 patients, nurses, doctors and pharmacists, and nearly 1,000 at-risk clinics about counterfeit drugs through Facebook ads, printed materials, and trainings. PSM has also been working with international partners in countries like India, China, and Brazil. The conference agenda includes a new panel format and presentations on new research studies.
Marv Shepherd conducted research exploring whether hospital pharmacies could be a source of diverted drugs. A survey of Texas hospitals found that 25% reported being contacted by "grey market" vendors weekly or daily to purchase pharmaceuticals. Additionally, over 85% of hospitals reported being contacted by such vendors in the last month to sell drugs. While the size of this illicit market is unknown, the findings suggest some hospitals may be unlawfully diverting drugs. Further analysis found no significant associations between vendor contacts and hospital size, ownership, or location. The research indicates opportunistic vendors are actively trying to obtain drugs from some hospitals in Texas.
PSM India aims to: raise awareness of spurious drugs' harm; educate consumers and practitioners on drug quality and identifying suspected spurious drugs; and collaborate with the government and WHO. PSM held an international workshop on ensuring patient safety over commercial interests and regaining consumer confidence. A study found many small manufacturers lack Good Manufacturing Practices compliance and risk producing spurious drugs. It evaluated 348 essential drugs across India to understand the spurious drug problem's full extent and compliance with regulations. PSM plans to expand detection technologies statewide and work with regulators against law-violating manufacturers.
The document summarizes a panel discussion on new developments in international cooperation to address challenges related to unapproved and counterfeit drugs. It describes problems like large quantities of prescription drugs coming from other countries and physicians ordering directly from unlicensed suppliers. Global challenges in investigations like tracing money and packages and obtaining evidence from other countries are also outlined. The panelists discuss international enforcement operations and USP programs that help strengthen quality assurance in developing countries.
The document summarizes initiatives to combat counterfeit medicines in various countries. It finds that healthcare professionals' roles are often unclear and they are not always at the forefront of counterfeiting issues. The WHPA campaign aims to strengthen advocacy for investing in healthcare professionals' education and capacity to detect, report, and prevent counterfeits. It establishes dialogue between stakeholders to share knowledge and resources and initiate cost-effective solutions. The WHPA Call to Action and toolkit provide strategies and resources to build comprehensive regional plans against counterfeiting through increasing professional capacity, regional cooperation, collaborative practice, and improved collaboration with authorities.
1. Partnership for Safe Medicines China (PSM China) was established in Beijing in November 2012 with participation from 12 associations to ensure a safe drug supply chain and educate patients and consumers on safe medication use.
2. PSM China's members include associations representing pharmaceutical manufacturers, distributors, hospitals, and licensed pharmacists.
3. In 2014, PSM China collaborated with Partnership for Safe Medicines India, launched a website, focused education efforts on medication for the elderly and chronic diseases, and organized over 180 volunteers to support educational programs.
The document discusses how American patients have been impacted by unsafe and counterfeit medicines from 2010-2013. It describes several cases where medical professionals purchased non-FDA approved drugs and devices, exposing patients to risks. This includes expired, stolen, or improperly stored medicines. The document outlines issues with specific treatments like IUDs, Botox, osteoporosis drugs, HIV drugs, and diabetes treatments. Patients who received counterfeit versions faced potential health problems. While the full scope of the counterfeit drug problem in the US is unknown, the document argues it threatens patient safety when healthcare providers and patients cannot be certain the treatments they receive are real and effective.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has developed a strategy to combat falsified medical products with the objective of reducing risks to patients and consumers. The strategy aims to enhance legal frameworks at the European Union and Council of Europe levels related to falsified medicines and strengthen safety features and controls for actors in the medical supply chain. It also addresses issues like internet sales of medicines and controls on active pharmaceutical ingredients.
Tom Kubic, President and CEO of the Pharmaceutical Security Institute (PSI) and PSM board member, presents an overview of global activity in the counterfeiting of prescription medicines in 2013.
This document summarizes a panel discussion on issues related to fake online pharmacies. The panelists included pharmacists, law enforcement agents, and policy experts. They discussed how online pharmacies are difficult to regulate due to their ability to operate across state and international lines. While organizations like the FDA and NABP have programs to verify legitimate online pharmacies, illicit sites still proliferate using search engines, social media, and other online marketing techniques. Research presented found that consumers have difficulty identifying unsafe pharmacy websites and are willing to purchase medicines from illegal online pharmacies without prescriptions, including drugs that require close medical supervision.
Non-FDA approved foreign drugs are being provided to Massachusetts patients through online pharmacies, putting their health at risk. These drugs may contain toxic fillers, expired ingredients, or lack important safety information. Several health groups and trusts in Massachusetts are directing patients to these online pharmacies to reduce costs, incentivizing the purchase of unsafe drugs. Records obtained through FOIA requests show thousands of patients across multiple regions in Massachusetts are affected. Next steps include alerting regulatory agencies to intervene.
Fighting black market and counterfeit drugs in America endangers patients. Any break in the regulated, closed supply chain - whether by patients buying drugs online, or medical professionals purchasing from unlicensed distributors - puts lives at risk. Counterfeit or improperly handled treatments for conditions like HIV/AIDS, osteoporosis, kidney disease, and diabetes can be ineffective or even life-threatening when patients' health depends on properly manufactured and stored medicine. Protecting the supply chain is crucial to patient safety.
The document thanks sponsors for supporting the 2013 Interchange conference. It provides information about materials available to attendees, including a 69-page overview of counterfeit drug policy in the conference packet and educational materials that can be co-branded or used to educate communities. A USB pen is also described that contains graphics, research, and consumer education materials from the Partnership for Safe Medicines.
Marv Shepherd, PSM president, Member USP Package Storage and Distribution Expert Committee, and Professor at the University of Texas at Austin speaks about updates to United States Pharmacopeia's good distribution practices.
Supply Chain Integrity: The Patient Care Interface by David Chen, The Society of Health-System Pharmacists
presented at the Partnership for Safe Medicines' 2012 Interchange on September 28, 2012.
Supply Chain Integrity: The Patient Care Interface by David Chen, The Society...
Similar to "The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How do these bad drugs get to our patients?" Congressional Briefing, March 7-8, 2016
RyMat Inc.: A Look At Generic vs. Brand PharmaceuticalsStuart Silverman
The document discusses generics vs brand name drugs and risks associated with generics. It notes that generics must have the same active ingredients and be within 10-25% of brand name drug concentrations to be approved. However, generics may have different inactive ingredients and manufacturing processes can vary, resulting in differences between generics. The document outlines issues found at some generic drug manufacturing plants in India and China, including falsifying data, poor quality control, and hiding failed test results. It warns that not all generics are equal and some imported from these countries may pose risks.
The document summarizes key findings from EvaluatePharma's 2014 Orphan Drug Report. It finds that worldwide orphan drug sales are forecast to reach $176 billion by 2020, almost double the growth of the overall prescription drug market. Orphan drugs are expected to account for 19.1% of worldwide prescription sales by 2020. The report also notes that Soliris, used to treat rare blood disorders, generates the highest revenue per patient of any orphan drug in the US.
High Cost of Prescription Drugs - What can we do about it?Vincent Rajkumar
This document discusses the high costs of cancer drugs and potential solutions. It notes that the average cost of new cancer drugs approved in 2014 was over $120,000 per year, creating financial hardship. It argues that drug companies' justifications for high prices, such as research costs, are overstated. The document proposes several approaches to control drug costs, including value-based pricing, importing drugs, increasing competition through generics, developing treatment guidelines, and allowing Medicare to negotiate prices. The goal is to balance drug access with pharmaceutical industry innovation and profits.
This document lists sponsors, exhibitors, and speakers for the Orphan Drugs & Rare Diseases Global Congress 2016 Europe conference. It provides an overview of the conference agenda which will focus on key issues impacting the orphan drugs industry such as commercialization, policies, reimbursement, pricing, and more. The two-day conference will provide networking and discussion opportunities between representatives from orphan drug manufacturers, big pharmaceutical companies, biopharmaceuticals, governments, patient groups, and others.
Four Effective Opioid Interventions for Healthcare LeadersHealth Catalyst
The crisis of opioid abuse in the U.S. is well known. What may not be so well known are the ways for clinicians and healthcare systems to minimize misuse of these addictive drugs. This article describes the risks for patients when they are prescribed opioids and the need for opioid intervention. It offers four approaches that healthcare systems can take to tackle the crisis while still relieving pain and suffering for the patients they serve:
Use data and analytics to inform strategies that reduce opioid availability
Adopt prescription drug monitoring programs to prevent misuse
Adopt evidence-based guidelines
Consider promising state strategies for dealing with prescription opioid overdose
Opioid misuse is a public health epidemic, but treatments are available and it’s time for those involved in the delivery of healthcare to change practices.
The document discusses direct-to-consumer (DTC) advertising of prescription drugs in the United States. It provides background on the history of DTC advertising and FDA regulation. Both supporters and critics of DTC advertising are discussed. Supporters argue that it educates patients, prompts discussions with doctors, and empowers consumers, while critics argue that it can mislead patients and inappropriately influence them to request drugs. Spending on DTC advertising by the pharmaceutical industry has risen dramatically in recent decades.
The document discusses direct-to-consumer (DTC) advertising of prescription drugs in the United States. It provides background on the history of DTC advertising and FDA regulation. Both supporters and critics of DTC advertising are discussed. Supporters argue that it educates patients, prompts discussions with doctors, and empowers consumers, while critics argue that it can mislead patients and inappropriately influence them to request drugs. Spending on DTC advertising by the pharmaceutical industry has risen dramatically in recent decades.
The document discusses direct-to-consumer (DTC) advertising of prescription drugs in the United States. It provides background on the history of DTC advertising and FDA regulation. Both supporters and critics of DTC advertising are discussed. Supporters argue that it educates patients, prompts discussions with doctors, and empowers consumers, while critics argue that it can mislead patients and inappropriately influence them to request drugs. Spending on DTC advertising by the pharmaceutical industry has risen dramatically in recent decades.
The document discusses counterfeit medicines, which the WHO defines as deliberately mislabeled drugs regarding identity and/or source. Counterfeits can include both branded and generic drugs with incorrect ingredients, dosages, or packaging. Medicines are targeted due to lax regulations in some countries, price differences globally, and the complexity of distribution systems. Counterfeits pose health risks as they provide ineffective treatment and can spread drug-resistant diseases. Stronger enforcement is needed across governments, industries, and distribution networks to prioritize combating counterfeit drugs.
The US Food and Drug Administration (FDA) regulates food, drugs, medical devices, vaccines, and other products in the United States. The FDA is responsible for protecting public health by ensuring the safety and security of these products. It evaluates the safety and efficacy of new drugs and monitors approved drugs for safety issues. The FDA aims to provide accurate science-based information to the public and encourages participation in its regulatory process through public dockets. It works with international authorities like those in India to ensure safety standards for products exported to the US.
The document discusses the growing heroin addiction epidemic in the United States. It notes that prescription opioid misuse has led many Americans to turn to heroin and that overdose deaths have more than tripled since 2010. It provides information on prevention and treatment efforts, including expanding access to the overdose reversal drug naloxone and increasing medically-assisted treatment programs. The document also discusses Walgreens' efforts to install safe drug disposal kiosks and make naloxone available without a prescription to help address the crisis.
This document provides an introduction to pharmacovigilance. It defines pharmacovigilance as the science relating to detecting, assessing, understanding, and preventing adverse drug reactions. The document outlines the need for pharmacovigilance due to limitations of clinical trials, medication errors, and adverse drug reactions being a leading cause of death. It describes Egypt's pharmacovigilance center and important terms like adverse drug reactions, adverse events, and serious reports. Healthcare professionals, patients, and marketing authorization holders should report valid adverse events containing identifiable information to the pharmacovigilance center.
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
Off-label drug use refers to when a drug is used in a way that is different from its FDA-approved label, such as being given in a different dose or route, or used to treat a different disease. While doctors can legally prescribe drugs off-label, drug companies cannot market drugs for off-label uses. Off-label drug use is common in cancer treatment because some cancer drugs work against many tumor types and cancer treatment is constantly evolving. When considering off-label drug treatment, patients should ask about the evidence and risks/benefits compared to approved drugs. The FDA could better regulate off-label use by systematically collecting post-market data on harms and benefits and disseminating reports on off-label evidence
Trisha Torrey advocates for lower prescription drug costs and encourages participation in advocacy campaigns. Many pharmacies offer cheaper generic "house brands" similar to national brands. Additionally, some drug companies benefit from FDA granted monopolies allowing them to set high prices. Congressional plans and some 2020 presidential candidates propose using international reference pricing and increased competition to lower drug costs in the US.
Trisha Torrey is a patient advocacy consultant who helps non-profit organizations promote access to affordable prescription drugs. While some pharmacies and drug companies benefit from lower costs or monopolies, importing drugs or joining Medicare drug plans can help individuals save on prescriptions. Several 2020 presidential candidates have proposed plans to lower drug prices by allowing government price negotiations or international reference pricing. Overall, voters agree that drug costs in the US are too high.
St. Louis Pharmaceutical Liability: Even Over-The Counter Medications Present...Jeffrey Lowe
If a manufacturer fails to alert the public to the potential risks of any types of drug or other product, the individual who is harmed by the drug can pursue a claim of damages.
Qui Tam: Off Label Drug Marketing [Data Snapshot]lawsuitlegal
When does the promotion of a pharmaceutical become illegal?
Learn what is considered off-label use for popular drugs and when it becomes unlawful in this data snapshot.
We share the most common types of off-label uses, where it happens most often, and what exceptions provide 'safe haven' protection.
Most doctors and hospitals are prescribing doctors as they should be, with the patients in mind.
However, off-label prescriptions are important when considered in relation to the False Claims Act. The issue of insurance reimbursement takes center stage when drugs are being used unlawfully and these healthcare organizations are receiving insurance payments for improper use.
So take a moment to review the data with us on Off-Label Marketing relating to qui tam actions, today.
Detection of Counterfeit Drugs and Other ProductsNancy Sperling
This document discusses the issue of counterfeit drugs and products. It provides statistics showing the vast scale of the counterfeit drug market globally and its health impacts. Specific drugs that have been counterfeited are listed. The document explores how counterfeits enter legitimate supply chains and the risks they pose to consumers. It outlines analytical methods used for detecting counterfeits and various anti-counterfeiting technologies and enforcement efforts. In addition to health concerns, it notes counterfeits violate pharmaceutical company patents and erode consumer trust in legitimate products.
Similar to "The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How do these bad drugs get to our patients?" Congressional Briefing, March 7-8, 2016 (20)
PSM presented a special webinar for families affected by counterfeits and fentanyl. Learn about opportunities to make your voice heard. You can watch the presentation at https://youtu.be/FmBv3Bb7ZHI
What have been the major crimes and policy developments in the space of counterfeit medicines? PSM reviews major prosecutions and legislation from the first half of 2021.
This document discusses concerns around safely implementing importation of drugs from Canada. It summarizes perspectives from experts in drug supply chain security and Canadian policy. They note that importation could undermine the Drug Supply Chain Security Act, as drugs from foreign markets don't use the same identifiers and documentation. It may also diminish Canada's drug supply and leave Americans without long-term solutions. The document outlines risks like counterfeiting and how Canadian authorities do not inspect all shipments. It questions whether importation could realistically work given these challenges to safety and oversight.
This document discusses why importing prescription drugs from Canada is not a viable solution to high drug costs in the US. It notes that previous state-level importation programs failed due to lack of savings and inability to adequately regulate foreign pharmacies. Proper testing of imported drugs is very expensive and would consume any savings. There are also safety concerns, as importation would undermine track-and-trace systems and Canada's drug supply is already limited. Law enforcement experts warn that importation could exacerbate the opioid crisis and organized crime may exploit regulatory loopholes. The document argues policymakers should focus on real solutions rather than unrealistic importation proposals.
Libby Baney, Executive Director for the Alliance for Safe Online Pharmacies talks about the current state of rogue online pharmacies and efforts to curb them.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Nano-gold for Cancer Therapy chemistry investigatory project
"The Insidious Path of Counterfeit Cancer Drugs from Turkey to Toledo: How do these bad drugs get to our patients?" Congressional Briefing, March 7-8, 2016
In July 2015, the Department of Justice indicted 8 individuals and 6 companies associated with CanadaDrugs.com, alleging that they sold $78 million worth of unapproved, mislabeled and counterfeit cancer drugs to American doctors between 2009 and 2012.
Canada Drug has been in the business of selling American citizens imported drugs that are not regulated by the FDA since 2001.
These illegally imported medicines, which passed through the United Kingdom and were received by dropshippers at 3 locations in the United States, included 2 lots of counterfeit Avastin and Altuzan.
The FDA's discovery of the counterfeit Avastin and Altuzan, which did not contain any active ingredient, led to a country-wide recall of Avastin in February 2012. In addition, the indictment provides evidence that the company knowingly sold unsafe medicines and deliberately covered up its role in the sale of counterfeit Avastin.
Sources:
Indictment
"Charges dropped against U.S. man accused in cancer-drug smuggling conspiracy," The Star, October 20, 2015, http://www.thestar.com/news/canada/2015/10/20/charges-dropped-against-us-man-accused-in-cancer-drug-smuggling-conspiracy.html.
"14 Execs Charged with Selling $78M in Counterfeit, Mislabled Drugs," Pharmaceutical Processing, August 18, 2015, http://www.pharmpro.com/news/2015/08/14-execs-charged-selling-78m-counterfeit-mislabled-drugs?et_cid=4750857&et_rid=866449022&type=headline.
"Federal Justice Department part of CanadaDrugs.com raid," CBCNews, March 27, 2015, http://www.cbc.ca/news/canada/manitoba/federal-justice-department-part-of-canadadrugs-com-raid-1.3011421.
"FDA Alert: Counterfeit Version Of Avastin In U.S. Distribution," Partnership for Safe Medicines, February 15, 2012, http://www.safemedicines.org/2012/02/fda-alert-counterfeit-version-of-avastin-in-us-distribution403.html.
In 2015 Pakistani citizen Junaid Qadir was indicted and then extradited from Germany to face charges that his company, JNS Impex, was a prescription drug wholesaler offering bulk counterfeit medications to U.S. fake drugs resellers.
According to the indictment, the defendants operated between 2006 and 2012, receiving orders via the internet, primarily from individuals and entities operating internet pharmacy websites and other types of illicit pharmacy operations.
These included fake onlne pharmacies in Florida, Arizona and Pennsylvania.
JNS Impex’s products included counterfeit and misbranded anxiety and seizure medicines, Viagra, and anabolic steroids
The case is a good illustration of the complexity of business processes in the counterfeit medicines trade.
Sources:
Press Release from DOJ: http://www.justice.gov/usao-co/pr/pakistani-man-makes-appearance-us-district-court-denver-following-indictment-and-arrest
ICE Release: https://www.ice.gov/news/releases/pakistani-man-indicted-and-arrested-selling-and-distributing-new-misbranded-and
On April 30, 2014, ihe Department of Justice unsealed a 73 count indictment against William "Liam" Scully and Shahrad Rodi Lameh, the president and vice-president of Pharmalogical, Inc, a Great Neck, New York-based company doing business as Medical Device King (MDK). (Scully was also the owner and operator of Taranis Medical Corporation (TMC) an unlicensed prescription drug wholesaler.)
Between February 2009 and July 2013, MDK and TMC imported misbranded and counterfeit prescription drugs from unlicensed wholesalers in the United Kingdom, Turkey, the Cayman Islands, Canada, United Arab Emirates, Switzerland and India
MDK misrepresented their products as FDA approved drugs to the approximately 1,000 medical practices that purchased them.
In many cases, these drug providers weren't licensed to distribute prescription medications in their own countries. They were entirely unregulated.
According to the indictment, Medical Device King's executives grossed $17 million in profits.
The drugs included cancer drugs, contraceptives (unapproved IUDs, subdermal contraceptive implants) and drugs for patients with kidney failure, multiple sclerosis, Crohn's disease and other chronic conditions.
Medical Device King was specifically responsible for selling counterfeit cancer drugs. In one case, the FDA was able to get a hold of the drug they sold before it was given to a patient and then lab tested it. It contained no active ingredient. In many other cases the medications were sold to clinics and administered before the FDA could capture and test them.
How many patients received fake cancer medication and lost their battles with cancer because of it?
Sharad Rodi Lameh pleaded guilty to 2 counts (conspiracy to commit wire fraud and conspiracy to distribute misbranded drugs) on October 16, 2014, forfeiting $500,000. Scully was convicted of 66 felony counts on November 12, 2015.
The Medical Device King case has had tremendous reach across the country; on May 13, 2013, FDA sent more than 1,000 letters to medical practices in 46 states that may have received prescription drugs from Pharmalogical, Inc., d/b/a Medical Device King.
Sources:
Robert E. Kessler, "Federal jury convicts Commack man of distributing unapproved drugs, officials say," News Day, November 17, 2015. http://www.newsday.com/long-island/nassau/william-scully-of-commack-convicted-of-distributing-unapproved-drugs-officials-say-1.11135936
Timothy Bolger, "Great Neck Rx Execs Sold Counterfeit Drugs," Feds Say, Long Island Press, April 30, 2014, http://www.longislandpress.com/2014/04/30/great-neck-rx-execs-sold-counterfeit-drugs-feds-say/
Robert E. Kessler, "Pharmalogical Inc. officers indicted in cancer drug fraud," feds say, News Day, April 30, 2014 http://www.newsday.com/long-island/nassau/william-scully-and-shahrad-rodi-lameh-charged-in-17m-prescription-cancer-drug-fraud-feds-say-1.7871937 (paywalled, but with pictures of the defendants).
"2 charged in $17M cancer drug fraud out of Great Neck-based pharmaceutical company Pharmalogical," Long Island News 12, http://longisland.news12.com/news/2-charged-in-17m-cancer-drug-fraud-out-of-great-neck-based-pharmaceutical-company-pharmalogical-1.7877453
Bill San Antonio, "Two indicted for selling fake meds" The Island Now, May 8, 2014, http://www.theislandnow.com/great_neck/news/two-indicted-for-selling-fake-meds/article_fcbd2382-d6c5-11e3-90f6-001a4bcf887a.html
"Businessmen charged with selling counterfeit drugs," The Washington Times, April 30, 2014, http://www.washingtontimes.com/news/2014/apr/30/ny-businessmen-face-drug-counterfeiting-charges/ (AP story)
Gallant Pharma International was an illegal drug importation business headquartered in Crystal City, Virginia that presented itself to U.S. medical facilities as a Canadian pharmaceutical company.
They sold low-cost drugs that were purported to be from Canada.
The 2013 indictment of Gallant Pharma charged 10 co-conspirators and the corporation itself with a series of charges that included introduction of misbranded drugs into interstate commerce, unlicensed medical wholesaling, wire fraud, importation contrary to law, and monetary transactions with criminally derived proceeds.
Between August 2009 and November 2011, the defendants generated at least $3.3 million from the sale of misbranded drugs to at least 54 doctors, medical practices, and hospitals in the United States.
Gallant Pharma specialized in wholesale distribution of “Brand Name and Generic products” for cosmetic surgery, plastic surgery, dermatology, pain management, neurology, anesthesiology, and oncology.”
The reality is that Gallant Pharma purchased their non-FDA approved drugs in bulk from foreign countries such as Turkey and India.
In May 2014, Gallant Pharma co-founder Syed “Farhan” Huda was sentenced to 3 years in prison and required to pay $3.4 million in restitution after pleading guilty to illegal importation, introducing misbranded drugs, unlicensed medical wholesaling and wire fraud, the Department of Justice (DOJ) reports.
According to the DOJ, to date, 12 individuals associated with Gallant Pharma have been convicted for their role in the illegal importation of prescription medication.
Source:
DOJ Press release: http://www.justice.gov/usao-edva/pr/illegal-drug-company-gallant-pharma-and-co-founder-sentenced
The well publicized counterfeit Avastin case (2012) is a good example of how difficult it is to assure the safety drugs imported outside FDA regulations, and to prosecute criminals selling substandard and counterfeit products.
Investigations showed that counterfeit Avastin moved from country to country with no authentication between sources.
The medication that ended up doctors’ offices from California to Illinois came from unauthorized distributors in the US.
Those people in turn purchased the medication from other unauthorized distributors from overseas where the medication wasn’t required to be inspected because it was “for export only.”
Back from the UK, to Denmark, to Switzerland, to Egypt, the original signatory for the medication came from an illiterate supplier who signed his name with an “X” before traveling across three countries and through six countries.
What jurisdiction did this crime occur in? Are the countries that passed the medication “for export only” through responsible? How do we protect patient safety when it’s so easy to pass the hot potato on to another party in another country?
In contrast, authentic Avastin comes from US manufacturing and is only distributed by five companies.
It’s not hard to keep track of legitimate suppliers of safe, effective medication or their products.
One of our board members received this mailing from Global Pharmacy Canada (Mississauga, Ontario, Canada). It’s the kind of advertising that reaches thousands of Americans every day
As It turns out, this company is NOT licensed to dispense medications in Canada. They possess no valid pharmacy license anywhere.
And even though they’re called Global Pharmacy Canada they send prescription orders to a pharmacy in India for filling.
In June 2013, this specific fake online pharmacy, which was based in Belize, was forced by the Ontario Court of Appeal to shut down offices in Toronto for violating Ontario’s professional pharmacy rules.
According to the ruling, Global Pharmacy Canada’s sales, purchases and orders were all processed through the Canadian call center, but the drugs were actually fulfilled by an unidentified “Indian pharmacist.”
The Justice who made the ruling noted that there was “no named pharmacist in India. There is no indication in any of the documentation sent to the client who the supplier of the drugs may be, and whether or not these drugs in fact come from an Indian pharmacist as represented, or from a supplier of drugs.”
Health Canada has warned that so-called “Canadian pharmacies” may not be in Canada at all. “Consumers should also be aware that there is no assurance that all claims made on the internet that a particular site is Canadian and / or a pharmacy, are reliable. Some internet sites may falsely claim to be a Canadian pharmacy and dispense foreign drugs that are unauthorized for sale in Canada.”
Source:
(http://www.safemedicines.org/2013/06/canadian-appeals-court-shuts-down-ontario-operations-of-global-pharmacy-canada539.html)
We have documentation that these unlicensed businesses are selling substandard medicines.
Texan residents Catherine Nix, Thomas Giddens and Wanda Hollis, for example, rented post office boxes under assumed names to receive at least 32 bulk shipments of prescription drugs from unlicensed sources in China, and broke them up into individual packages for resale. Drugs included Xanax, phentermine, Cialis and Viagra, Valium and Stilnox (and more).
The confiscated pills were tested and confirmed to be counterfeit and substandard. Pills marketed as "name brand" Xanax, for example, were only 36% as strong as they should have been; the generic of Xanax, alprazolam, actually contained chlorpheniramine, diazepam and pIlls purporting to be Valium and Stilnox only contained melatonin.
In truth, consumers are lucky if their illegally imported medication is just expired or substandard. Investigators have found counterfeit drugs:
Contaminated with heavy metals
Adulterated with rat poison, boric acid, antifreeze, PCBs and benzopyren
Filled with floor wax, brick dust, sheet rock, house paint, road paint, or paint thinner
Sold with substitute drugs that haven’t been approved by the FDA and may cause dangerous side effects
These kinds of substitutions can literally kill consumers.
Since 2009, 39 individuals in 7 states have been prosecuted for the purchase or sale of non-FDA approved intrauterine devices (IUDs).
In 2010 the FDA issued a letter to healthcare providers warning that the effectiveness of black market IUDs could not be guaranteed, that they may have been manufactured or shipped in unsafe conditions and that billing for unapproved medical products could result in prosecution for insurance fraud.
In 2012, researchers found that illicit online pharmacies were selling IUDs and teaching self-insertion with cartoons on YouTube.
In September 2012, the FDA issued letters warning 23 US. medical practices in 11 states that they may have purchased unapproved versions of the osteoporosis treatments Prolia and Aclasta from unlicensed wholesalers.
Since 2007, more than 16 physicians and drug distributors have been prosecuted for the purchase or sale of non-FDA approved cancer treatments. The FDA continues to conduct investigations.
Since 2011, the FDA has notified more than 100 medical practices in 29 states that they may have purchased counterfeit cancer medications which were distributed by a fake online Canadian pharmacy.
Some of the tested counterfeit cancer medication contained no active ingredients--only saline and acetone. Illegal distributors make a profit selling drugs that are illegally imported, expired, stolen, damaged by bad handling or outright counterfeits.
Since 2005, at least 46 individuals in 16 states have been investigated for the purchase or sale of non-FDA approved cosmetic drugs—a variety of substances being passed off as Botox, collagen or other injected cosmetic treatments.
Among those charged, 37 have pleaded guilty or beenconvicted in court, while the rest are still under investigation.
During the same time period, 1 patient died and at least 11 others sought medical treatment for disfigurement or serious illness brought on by these black market injections.
In 2012, the FDA notified 350 medical practices in 43 states that they may have purchased counterfeit Botox and since then more than 700 doctors across all therapeutic areas have received letters warning them that they may have purchased non-FDA approved drugs.
Substandard medical devices could fail for reasons that are entirely unclear if there's no evidence they were counterfeit.
Or they could contain heavy metals or contaminants that compromise patients' health.
Finally, substandard therapies breed resistant strains of infection.
The WHO has noted that interrupted treatment and substandard counterfeit drugs have caused a worldwide surge in drug resistant malaria. Drug resistant TB is also on the rise.
The CDC has identified many life threatening drug resistant strains of common illnesses, among them MRSA, strep, TB, gonorrhea and Bacterial Meningitis. Counterfeits have caused needless suffering and death overseas. Protecting our safe medical supply can discourage drug resistant infections here.
WHO, Global report on antimalarial drug efficacy and drug resistance: 2000–2010, http://apps.who.int/iris/bitstream/10665/44449/1/9789241500470_eng.pdf
In 2012 and 2013 alone, the FDA warned at least 1000 medical practices in 46 states that they had been buying imported prescription medicine from illegal distributors who had been selling counterfeit and substandard products.
In addition to that trade, countless Americans are importing unregulated drugs from unlicensed online pharmacies.
This is a significant threat to Americans, and it’s affecting people in your state.